NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Viveon Health Acquisition Corp. VHAQ VHAQW, VHAQR, VHAQU))), a special purpose acquisition entity (the “Company”), announced today that it held an extraordinary meeting of shareholders (the “Adjourned Extraordinary Meeting”) on January 20, 2023 to, among other things, approve the Company proposal to consummate its previously announced initial business combination with Suneva Medical, Inc. At the adjourned special meeting, shareholders voted to adjourn the meeting until February 3, 2023 at 12:00 p.m. Eastern Time.

As of January 17, 2023 (after including the 3,188,100 shares redeemed by Viveon in connection with the 2022 Annual General Meeting held on December 23, 2022), there were 6,876,024 Viveon common shares outstanding, of which 5,031,250 are charter shares and are not subject to redemption. As of January 18, 2023 (the final date for redemption requests related to the adjourned special meeting to approve the proposed business combination), Continental Stock Transfer & Trust Company, as trustee, received requests to redeem 1,798,631 Viveon common shares. These shares would only be redeemed upon the consummation of the business combination. As of this date, approximately $19.68 million is held in escrow.

Participants in the invitation to the adjourned special session

The Company and its directors and officers may be considered participants in the solicitation of proxies from the Company’s stockholders in respect of the proposals of the adjourned special meeting. A list of the names of these directors and officers and a description of their interests in the Company is available in the Registration Document on Form S-4, effective November 14, 2022, and the definitive proxy statement/prospectus therein dated dated November 14, 2022, which was mailed to shareholders of the Company on November 21, 2022, amended on November 23, 2022. The…